Physician profile
Adam K Ashton
NPI 1609855501
$1,568,447.48
in general payments reported to CMS, 2019-2025
36 companies · $305K in 2025
The $305K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256K · 2020: $80K · 2021: $158K · 2022: $194K · 2023: $291K · 2024: $285K · 2025: $305K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $507K · Consulting Fee: $204K · Travel and Lodging: $83K · Honoraria: $60K · Food and Beverage: $25K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,875 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $506,730.63 |
| Consulting Fee | $203,976.50 |
| Travel and Lodging | $82,867.50 |
| Honoraria | $59,741.00 |
| Food and Beverage | $25,459.30 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,875.00 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $404,158.09 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $257,381.74 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192,704.11 | 2020-2025 | Caplyta |
| Allergan, INC. | $143,736.91 | 2019-2021 | |
| Abbvie INC. | $138,061.18 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $111,620.58 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $101,298.19 | 2019-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $74,436.42 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $44,636.69 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $21,923.20 | 2019-2025 | Spravato |
| Eisai INC. | $20,820.94 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $19,421.43 | 2021-2025 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $10,001.57 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,496.21 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $6,253.57 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,224.90 | 2021-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $1,982.24 | 2019-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $1,627.78 | 2019-2024 | |
| Lundbeck LLC | $1,395.23 | 2019-2025 | Rexulti, Brintellix |
| Corium, LLC | $1,376.99 | 2022-2025 | Azstarys, Azstarys |
| Vanda Pharmaceuticals INC. | $641.00 | 2019-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $616.49 | 2019-2025 | Wellbutrin, Aplenzin |
| Idorsia Pharmaceuticals US INC | $430.84 | 2022-2024 | Quviviq |
| Neos Therapeutics, Lp | $266.10 | 2019-2020 | |
| Almatica Pharma LLC | $247.93 | 2021-2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $226.49 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $123.03 | 2019-2022 | |
| Alfasigma USA, INC. | $116.40 | 2020-2022 | |
| Noven Therapeutics, LLC | $68.85 | 2024 | Xelstrym, Secuado |
| Acadia Pharmaceuticals INC | $34.25 | 2021-2023 | Nuplazid |
| Vertical Pharmaceuticals, LLC | $30.48 | 2019 | |
| Neuronetics, INC. | $23.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.23 | 2019 | |
| Luye Pharma (USA) Ltd. | $14.34 | 2025 | Erzofri Extended-Release |
| Owp Pharmaceuticals, INC. | $13.93 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Ashton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.